ArticleProstate cancer and prostatic diseases2021
Patient- and tumor-level risk factors for MRI-invisible prostate cancer.
Article in Prostate cancer and prostatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Analysis of risk factors for MRI-invisible prostate cancer-the significance of AGGF1 immunohistochemical detection and PSAD.The Canadian journal of urology · 2026Article
- Label-free fluorescence lifetime imaging for rapid discrimination of high-grade prostate cancer in fresh biopsy cores: a feasibility study.Journal of biomedical optics · 2026Article
- Analysis of gray zone PSA and PSAD correlated with PIRADS v2.1 in the MRI-US fusion prostate biopsy era: a retrospective bi-centre study.International urology and nephrology · 2025Article
- Investigating MRI-Associated Biological Aspects of Racial Disparities in Prostate Cancer for African American and White Men.Journal of magnetic resonance imaging : JMRI · 2025Article
- The state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement.Prostate cancer and prostatic diseases · 2024Article
- Concerns regarding prostate cancer screening guidelines in minority populations.Prostate cancer and prostatic diseases · 2024Article
- Negative magnetic resonance imaging cannot be used to omit an initial prostate biopsy - An ambispective study.Prostate international · 2024Article
- MRI-Targeted Prostate Fusion Biopsy: What Are We Missing outside the Target? Implications for Treatment Planning.Current oncology (Toronto, Ont.) · 2024Article
- Comparing 12-core and 20-core biopsy for prostate cancer diagnosis with transperineal MR/US fusion biopsy: assessing the effective number of systemic cores using propensity score matching.International urology and nephrology · 2023Article
- Comparison of Prostate-Specific Antigen and Its Density and Prostate Health Index and Its Density for Detection of Prostate Cancer.Biomedicines · 2023Article
- Landmarks in the evolution of prostate biopsy.Nature reviews. Urology · 2023Review
- Side-specific, Microultrasound-based Nomogram for the Prediction of Extracapsular Extension in Prostate Cancer.European urology open science · 2023Article
- A triple-classification for differentiating renal oncocytoma from renal cell carcinoma subtypes and CK7 expression evaluation: a radiomics analysis.BMC urology · 2022Article
- Identifying Risk Factors for MRI-Invisible Prostate Cancer in Patients Undergoing Transperineal Saturation Biopsy.Research and reports in urology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiparametric MRI is highly sensitive for detection of clinically significant prostate cancer, but has a 10-20% false negative rate. It is unknown if there are clinical factors that predict MRI invisibility. We sought to identify predictors of MRI-invisible (MRI(-)) disease.
methodsMen undergoing MRI/US-fusion targeted + systematic biopsy by two surgeons at our institution from 2015 to 2018 were reviewed. Patient demographics, clinical data, MRI metrics, and biopsy pathology results were obtained by chart review. An MRI(-) tumor was defined as a positive systematic biopsy in a zone without an MRI lesion. Factors associated with presence of MRI(-) tumors were identified using stepwise multivariable logistic regression.
resultsOf 194 men included in the analysis, 79 (41%) and 25 (13%) men had GG1+ and GG2+ MRI(-) tumors, respectively. On multivariable analysis, only Black race was associated with presence of GG1+ MRI(-) tumors (OR 2.2, 95% CI 1.02-4.96). Black race (OR 3.5, 95% CI 1.24-9.87) and higher PSA density (OR 2.0, 95% CI 1.34-3.20) were associated with presence of GG2+ MRI(-) tumors. In non-Black and Black men, detection of MRI(-) tumors on systematic biopsy upgraded patients from no disease to GG2+ disease 1% and 11% of the time, respectively, and from GG1 to GG2+ disease 42% and 60% of the time, respectively.
conclusionsBlack race and PSA density were associated with presence of MRI(-) prostate cancer. Further study on racial differences is warranted based on these results. Surgeons should consider pre-biopsy risk factors before deciding to omit systematic prostate biopsy regardless of mpMRI results.
Indexed as
Identifiers
33568751What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.